Starling Oncology, Inc. (STLN) Stock Score, Valuation & Financial Research

Starling Oncology, Inc. is in the Healthcare sector and Medical - Care Facilities industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for STLN

Starling Oncology, Inc. does not currently have a complete Wall Street Score. The stored market price is USD 6.36. These figures are a research snapshot, not a buy or sell recommendation.

What Starling Oncology, Inc. does

Starling Oncology, Inc., formerly The Oncology Institute, is a value-based oncology company advancing cancer care in the community setting. Founded in 2007, the company offers cutting-edge, evidence-based cancer treatments, including clinical trials and transfusions, to a large patient population. It operates as an integrated oncology platform serving patients, providers, and health plans across multiple markets with a focus on delivering high-quality, patient-centered care.

Company business and revenue

Research reporting period: 2025-12-31. A research update is not a new financial filing.

How the company makes money

Starling Oncology operates a value-based community oncology model, generating revenue primarily through the delivery of cancer care services, including chemotherapy, radiation therapy, and clinical trials. The company enters into capitated and risk-sharing arrangements with health plans and providers, receiving fixed payments to manage the total cost of care for oncology patients.

Products and services

  • The company provides comprehensive cancer care services including medical oncology, radiation oncology, pharmacy services, clinical trials, and supportive care in community-based settings.

Customer types

Health plans and insurance providers; Individual cancer patients.

Suppliers, materials and equipment

  • Pharmaceutical and medical supply distributors — The company relies on various third-party distributors for the procurement of oncology drugs and medical supplies used in patient treatment. Source

Competitors and product-market comparisons

  • Hospital-based oncology departments — Large health systems that provide comprehensive cancer care and compete for patient referrals and health plan contracts. Source

Business strengths to evaluate

  • Value-based care delivery model Source
  • Extensive network of community-based clinics Source

Business risks and research considerations

  • Dependence on health plan contracts and reimbursement rates Source
  • Regulatory and compliance risks in healthcare Source

Sources: Company research source

Company research refreshed 2026-10-12. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

STLN financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 6.36
Market capitalization:
635.45M (currency not supplied)
Revenue:
USD 587.24M
Net income:
USD -36.29M
Free cash flow:
USD -27.79M
Cash:
USD 41.09M
Total debt:
USD 104.48M
EPS:
USD -0.30

What stands out

  • Reported year-over-year revenue growth is +16.8%.
  • Free cash flow is USD -27.79M, negative for the stored period.
  • The balance sheet shows USD 41.09M of cash versus USD 104.48M of total debt, with debt exceeding cash on these two reported measures.
  • The current research record carries a limited financial history warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Free cash flow is -4.7% of stored revenue. This is a simple cross-field ratio, not a verified same-period cash conversion margin; confirm reporting periods before comparison.
  • Net income equals -6.2% of stored revenue. This is an indicative ratio only; accounting periods and units should be verified in filings.
  • Debt exceeds cash by USD 63.38M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for STLN

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • Can STLN maintain its current revenue growth rate and improve the amount of that revenue that turns into earnings and cash?
  • How long can STLN fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • Is STLN's debt load manageable relative to cash generation, interest costs and upcoming maturities?
  • What specifically needs to improve for STLN to reach sustainable profitability?
  • What does the current limited financial history warning mean for the reliability or interpretation of STLN's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-01.

Research-input completeness: 64% of the scoring inputs required for this public page are currently available.

How to research STLN

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.